TY - JOUR
T1 - Effect of atorvastatin on subclinical atherosclerosis in virallysuppressed HIV-infected patients with CMV seropositivity
T2 - a randomized double-blind placebo-controlled trial
AU - Yunihastuti, Evy
AU - Rusdi, Lusiani
AU - Azizi, Muhammad Syahrir
AU - Estiasari, Riwanti
AU - Wulandari, Endah Ayu T.
AU - Purnamasari, Dyah
AU - Noviar, Mutiara Shinta
AU - Nasution, Sally Aman
AU - JASIRWAN, CHYNTIA OLIVIA MAURINE
N1 - Funding Information:
Grant information: This trial is partly funded by Ministry of Research and Technology with funding number 173/SP2H.
Publisher Copyright:
© 2021. Yunihastuti E et al.
PY - 2021
Y1 - 2021
N2 - Background: Persistent immune activation and inflammation in HIVinfection are linked to excess cardiovascular risk and other noncommunicable diseases. Periodic asymptomatic CMV-reactivity in HIV infected patients over a lifetime may contribute to non-AIDS defining morbidity. Despite undetectable levels of HIV and CMV, these patients continue to have increased levels of biomarkers and immune activations. Statin administration is thought to reduce subclinical atherosclerosis by decreasing LDL-C levels. It may also add beneficial effects against CMV infection. Methods: We are conducting a double-blind placebo-controlled trial in which patients are randomized to receive either atorvastatin or placebo with a ratio of 1:1. This trial aims to study the effect of atorvastatin in statin-naive virally-suppressed HIV-infected patients with stable ART and CMV seropositivity on carotid intima media thickness (CIMT), tool that evaluates subclinical atherosclerosis. The study recruits 80 patients at HIV integrated care unit of Cipto Mangunkusumo hospital. All eligible subjects have CIMT evaluation as primary outcome, along with flow mediated vasodilatation (FMD), liver fibrosis and steatosis evaluation, fasting lipid, neurocognitive test, community periodontal index (CPI), and residual immune activation as secondary outcomes in 48 weeks. Ethics and dissemination: This study has received an ethical approval from Health Research Ethics Commitee–Universitas Indonesia and Cipto Mangunkusumo Hospital. Before joining the study, all participants fill in an informed consent form. At the end of study analysis, the trial results will be published and disseminated in peerreviewed journals. Discussion: The main purpose of our study is to evaluate the effect of atorvastatin administration on CIMT changes in statin naïve virally suppressed HIV-infected patients with stable ART and CMV seropositivity Registration: ClinicalTrials.gov ID NCT04101136; registered on 24 September 2019.
AB - Background: Persistent immune activation and inflammation in HIVinfection are linked to excess cardiovascular risk and other noncommunicable diseases. Periodic asymptomatic CMV-reactivity in HIV infected patients over a lifetime may contribute to non-AIDS defining morbidity. Despite undetectable levels of HIV and CMV, these patients continue to have increased levels of biomarkers and immune activations. Statin administration is thought to reduce subclinical atherosclerosis by decreasing LDL-C levels. It may also add beneficial effects against CMV infection. Methods: We are conducting a double-blind placebo-controlled trial in which patients are randomized to receive either atorvastatin or placebo with a ratio of 1:1. This trial aims to study the effect of atorvastatin in statin-naive virally-suppressed HIV-infected patients with stable ART and CMV seropositivity on carotid intima media thickness (CIMT), tool that evaluates subclinical atherosclerosis. The study recruits 80 patients at HIV integrated care unit of Cipto Mangunkusumo hospital. All eligible subjects have CIMT evaluation as primary outcome, along with flow mediated vasodilatation (FMD), liver fibrosis and steatosis evaluation, fasting lipid, neurocognitive test, community periodontal index (CPI), and residual immune activation as secondary outcomes in 48 weeks. Ethics and dissemination: This study has received an ethical approval from Health Research Ethics Commitee–Universitas Indonesia and Cipto Mangunkusumo Hospital. Before joining the study, all participants fill in an informed consent form. At the end of study analysis, the trial results will be published and disseminated in peerreviewed journals. Discussion: The main purpose of our study is to evaluate the effect of atorvastatin administration on CIMT changes in statin naïve virally suppressed HIV-infected patients with stable ART and CMV seropositivity Registration: ClinicalTrials.gov ID NCT04101136; registered on 24 September 2019.
KW - atherosclerosis
KW - atorvastatin
KW - cognitive dysfunction
KW - cytomegalovirus
KW - HIV
KW - non alcoholic fatty liver
KW - periodontitis
UR - http://www.scopus.com/inward/record.url?scp=85117326016&partnerID=8YFLogxK
U2 - 10.12688/F1000RESEARCH.28262.1
DO - 10.12688/F1000RESEARCH.28262.1
M3 - Article
AN - SCOPUS:85117326016
SN - 2046-1402
VL - 10
SP - 1
EP - 11
JO - F1000Research
JF - F1000Research
ER -
